JonesTrading analyst Soumit Roy has maintained their bullish stance on TARA stock, giving a Buy rating today.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Soumit Roy’s rating is based on Protara Therapeutics’ progress with their bladder cancer drug, TARA-002, which is moving into a pivotal study for BCG-Naive patients. The company has received alignment from the FDA to conduct this trial, which will compare TARA-002 against physician’s choice of intravesical-delivered chemotherapy.
The trial’s primary endpoint is set as complete response (CR) at six months, which is considered a straightforward measure compared to other trials. Additionally, Protara has provided benchmarks for CR rates based on historical data, which supports the potential efficacy of TARA-002. These factors, combined with the company’s financial stability, contribute to the Buy rating.
In another report released today, LifeSci Capital also maintained a Buy rating on the stock with a $26.00 price target.